Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Chronic Graft-versus-host-disease Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Chronic Graft-versus-host-disease. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Chronic Graft-versus-host-disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 50% (1 studies); the largest phase groups are Phase 3: 1, Phase 2: 1.

Research is led by Incyte Corporation (1), M.D. Anderson Cancer Center (1), Navy General Hospital, Beijing (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is INCA034176 (drug, 1 trial), followed by Placebo, Corticosteroids.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
1
Phase 3 Trials
3
Sponsors

Track Chronic Graft-versus-host-disease trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 3NCT06585774

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic...

Sponsor: Incyte CorporationEnrolling: 24020 locations
RECRUITINGNCT07127926

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 81 location
RECRUITINGPhase 2NCT02918188

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.

Sponsor: Navy General Hospital, BeijingEnrolling: 211 location

Frequently Asked Questions

There are currently 3 clinical trials for Chronic Graft-versus-host-disease, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Chronic Graft-versus-host-disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Chronic Graft-versus-host-disease, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.